YY 001 - Shanghai Yuyao Biotech
Alternative Names: YY-001 - Shanghai Yuyao BiotechLatest Information Update: 04 Sep 2024
At a glance
- Originator Shanghai Yuyao Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; Gastric cancer; Prostate cancer
- Phase I Solid tumours
Most Recent Events
- 04 Sep 2024 Phase-II clinical trials in Colorectal cancer (Combination therapy) in China (PO) (Shanghai Yuyao Biotech pipeline, September 2024)
- 04 Sep 2024 Phase-II clinical trials in Gastric cancer (Combination therapy) in China (PO) (Shanghai Yuyao Biotech pipeline, September 2024)
- 04 Sep 2024 Phase-II clinical trials in Prostate cancer (Combination therapy) in China (PO) (Shanghai Yuyao Biotech pipeline, September 2024)